3M Pharmaceuticals (NYSE: MMM) 3M is a $21 billion diversified technology company with leading positions in consumer and office; display and graphics; electronics and telecommunications; health care; industrial and transportation; safety, security and protection services and other businesses.

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing patient-specific products for the repair or regeneration of human tissues, utilizing the Company's proprietary adult stem cell technology. Aastrom's proprietary Tissue Repair Cells (TRCs), a mix of bone marrow-derived adult stem and progenitor cells, are manufactured in the AastromReplicell® System, an industry-unique automated cell production system. Aastrom's TRC cell products are in clinical trials for the following therapeutic indications: severe bone fractures (U.S.: Phase I/II - multi-center; EU: Phase I/II - multi-center), ischemic vascular disease (EU: Phase I/II), jaw bone reconstruction (EU: proof of concept) and spine fusion (U.S.: Phase I/II - single-center). The Company has recently reported positive clinical trial results for its TRCs demonstrating both the clinical safety and ability of TRCs to induce healthy new tissue growth.

ABAXIS, Inc. (Nasdaq: ABAX) ABAXIS develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform 23 different assays and 8 different profiles on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

ABBOTT LABORATORIES (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 60,000 people and markets its products in more than 130 countries.

Abgenix (NasdaqNM:ABGX) Abgenix is a biopharmaceutical company focused on the discovery, development and manufacturing of human therapeutic antibodies. The company's antibody development platform includes a leading technology and state-of-the-art manufacturing capabilities that enable the rapid generation, selection and production of high affinity, fully human antibody product candidates to a variety of disease targets. Abgenix leverages its leadership position in human antibody technology to build a diversified product portfolio through the establishment of collaborations with multiple pharmaceutical and biotechnology companies. For more information on Abgenix, visit the company's website at www.abgenix.com.

ABIOMED INC (NasdaqNM:ABMD) Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000(TM) Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In Europe, ABIOMED offers the IMPELLA® RECOVER® minimally invasive cardiovascular support systems under CE Mark approval. The Company's AbioCor® Implantable Replacement Heart was the subject of an initial clinical trial under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial.

ABLE LABORATORIES (Other OTC: ABLSQ.PK) Able Laboratories, Inc. is a developer and manufacturer of generic pharmaceutical products in tablet, capsule, liquid and suppository dosage forms. In May 2005, Able suspended manufacturing and distribution of its entire product line. The company currently is not generating income or revenue, because of its suspension of manufacturing operations and product recalls. The company has filed a petition to reorganize under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of New Jersey, Trenton Division on July 18, 2005.

Acadia Pharmaceuticals Inc.  (NasdaqGM: ACDAD) is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.

ACAMBIS PLC ADS (NasdaqNM:ACAM) Acambis is a biotechnology company discovering, developing and manufacturing novel vaccines to prevent and treat infectious diseases. We are based in Cambridge, UK and Cambridge, Massachusetts, USA.

Accentia Biopharmaceuticals, Inc. (NasdaqGM: ABPI) is a vertically-integrated biopharmaceuticals company focused on the acquisition, development and commercialization of late stage specialty pharmaceuticals and biologics for targeted therapeutics.

Aclara Biosciences Inc (NASDAQ NM) Develop, manufacture and supply of innovative biology assays as part of the eTag TM Assay System. The System comprises of reagent kits, software and services that simplify and automate various aspects of drug development, pre-clinical testing and clinical assessment. The Company's eTag assays represent a universal platform for the analysis of genes, proteins and cellular pathways and can be analyzed using existing capillary electrophoresis instrumentation systems. The eTag assays applicable in the development of the new paradigm of molecular medicine for patient-specific therapeutic treatments based on individual genotypes and phenotypes derived from predictive biomarkers. The Company develops and commercializes these high content assays initially in the target areas of oncology and toxicogenomics.

Acorda Therapeutics, Inc. (NasdaqGM: ACOR) engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis, spinal cord injury, and other disorders of the central nervous system.

Acrongenomics, Inc. (OTCBB: AGNM) is a Research & Development nanobiotechnology company pioneering the development of uniquely advanced nanomolecular diagnostics for the Life Sciences Industry. The Company seeks to establish its proprietary nanotechnology platform as a standard in Molecular In Vitro Diagnostics. Acrongenomics is dedicated to transforming scientific concepts into reality, as it has successfully applied Nanotechnology inspirations into next-generation Biotechnology applications.

Adherex Technologies Inc. (AMEX: ADH) a development stage biopharmaceutical company, engages in the discovery and development of novel cancer therapeutics.

Adolor Corp (NASDAQ NM) discover, develop and market proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by current pain treatments. The Group is in the development stage. The Group has a portfolio of small molecule product candidates that are in various stages of development ranging from pre-clinical studies to Phase I through Phase III clinical trials. Its product candidate, alvimopan, also known as ADL 8-2698, is designed to selectively block the effects of narcotic analgesics on the gastrointestinal tract. It has obtained licenses from Kwang Dong Pharmaceutical Co Ltd and Santen Pharmaceutical Co Ltd of Japan to develop and market dermal formulations of ADL 2-1294 in South Korea and North Korea for dermal pain and ophthalmic pain respectively.

Advanced Cell Technology Inc. (OTCBB:ACTC.OB) engages in the development and commercialization of human stem cell technology in the fields of regenerative medicine and stem cell therapy in the United States. The company offers RPE cells for the treatment of age-related disease of the eye, including macular degeneration; hemangioblast cells for the treatment of various blood and cardiac disorders; and dermal cells for the treatment of dermal damage, including burns, wound repair, and surgery.

Advanced Life Sciences Holdings, Inc. (NasdaqGM: ADLS) development stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs in the areas of infectious disease, inflammation, and oncology.

Advanced Magnetics Inc. (AMEX) Advanced Magnetics, Inc. is a developer of superparamagnetic iron oxide nanoparticles used in pharmaceutical products. As a leader in our field, we are dedicated to the development and commercialization of our proprietary nanoparticle technology for use in therapeutic iron compounds to treat anemia, as well as novel imaging agents to aid in the diagnosis of cardiovascular disease and cancer. For more information about us, please visit our website at http://www.advancedmagnetics.com , the content of which is not part of this press release.

Advanced Photonix, Inc. (AMEX) develop and manufacture optoelectronic semiconductor based components, hybrid assemblies and other proprietary advanced solid state light and radiation detection devices. The Group designs and manufactures silicon-based electro-optical components, assemblies and design solutions for a global original equipment manufacturers (OEMs) customer base. The products include customer specific assemblies for fiber optic data and telecommunications, PIN photodetectors, photodetector hybrids, military and commercial aerospace products, custom optoelectronic assemblies and FILTRODE(R). The Group also supplies detectors for high reliability (Hi-Rel) applications, including military and commercial aerospace and other applications requiring Hi-Rel specifications.

Advaxis Inc. (OTCBB: ADXS.OB) a development stage biotechnology company, engages in the research and development of cancer vaccines. It focuses on developing cancer vaccines targeting cervical, breast, prostate, ovarian, lung, and other cancers.

ADVENTRX Pharmaceuticals (Amex: ANX) is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that surpass the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance.

Aeterna Laboratoires, Inc. (NasdaqNM: AELA ) With its wholly-owned subsidiary Zentaris GmbH, is a biopharmaceutical company with an extensive product portfolio, including 2 already marketed and several other products at early and late- stage development in endocrinology, oncology and infectious diseases. Cetrorelix (Cetrotide(r)) is sold in the U.S. and Europe to the in vitro fertilization market, and is in Phase II clinical trials for endometriosis, uterus myoma and enlarged prostate (BPH). Miltefosine (Impavido(r)) is sold for black fever and has successfully completed a Phase III trial in parasitic skin disease. Neovastat(r) is in a Phase III trial for non-small cell lung cancer. Several other clinical programs are underway with various potential development candidates, supported by a worldwide network of scientific and marketing partnerships. Furthermore, AEterna benefits from a discovery platform of 100,000 molecules which is generating promising new compounds.

Aethlon Medical, Inc. (OTCBB: AEMD) is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the Hemopurifier(TM) to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur. 

Affymetrix Inc (Nasdaq:AFFX) Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip® technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,300 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company has about 1,000 employees worldwide.

Akorn, Inc. (AMEX: AKN) Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals.

Akzo Nobel N.V.(NasdaqNM: AKZOY) Akzo Nobel N.V. operates as a technology-based company, which provides healthcare products, coatings, and chemicals to the customers worldwide. Its Pharma segment engages in the research, development, manufacture, sale, and service of human and animal healthcare products, including prescription medicines, veterinary products, and active pharmaceutical ingredients. The company’s Coating segment produces paints, finishes, stains, and synthetic resins for industrial applications, professional painters, and the do-it-yourself sector. Its product areas include decorative/architectural paint, car refinishes, liquid and powder coatings for industrial use, marine and yacht coatings, protective coatings, aerospace coatings, and industrial and consumer adhesives. Akzo Nobel’s Chemicals segment is a mix of specialty, functional, and commodity chemicals based on the positions in certain segments of the chemical industry. Its products consist of pulp bleaching chemicals; speciality resins; surfactants and fatty acids; water treatment chemicals; chlorine and caustic soda; polymerization catalysts; and salt for electrolysis, other chemical industries, food applications, and consumer use. The company operates primarily in Europe, North America, Latin America, Asia, the Middle East, and Africa. The company was founded 1911 and is headquartered in Arnhem, the Netherlands.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life- threatening medical conditions. Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders.

Alfacell Corporation (Nasdaq: ACEL) is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other diseases, using its ribonuclease (RNase) technology platform. ONCONASE® (ranpirnase), Alfacell's lead investigational drug candidate, is currently being evaluated in several studies, including a Phase IIIb registration study for malignant mesothelioma (MM) and a Phase I/II trial in Non-Small Cell Lung Cancer (NSCLC).

Align Technology, Inc. (Nasdaq: ALGN) manufactures and markets Invisalign, a proprietary method for treating malocclusion, or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. Because it does not rely on the use of metal or ceramic brackets and wires, Invisalign significantly reduces the aesthetic and other limitations associated with braces. Invisalign is appropriate for treating adults and older teens. Align Technology was founded in March 1997 and received FDA clearance to market Invisalign in 1998.

Alnylam Pharmaceuticals Inc. (NasdaqGM: ALNY) engages in the development of drugs that work through RNA interference system in the United States. Its principal drug candidate comprises ALN-RSV01, a phase I clinical stage product for the treatment of lung infections caused by respiratory syncytial virus.

Altus Pharmaceuticals Inc. (NasdaqGM: ALTU) engages in the development and commercialization of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders. It utilizes its proprietary protein crystallization technology to develop protein therapies.

Amarillo Biosciences Inc. (OTCBB: AMAR.OB) engages in the research and development of biologics for the treatment of human and animal diseases in the United States. It focuses on human health indications for the use of low-dose orally administered natural human interferon alpha, principally for the treatment of Sjogren's syndrome, Behcet's disease, polycythemia vera, essential thrombocythemia, idiopathic pulmonary fibrosis, and oral warts in HIV+ patients.

Amazon Biotech Inc. (OTCBB: AMZB.OB) a development stage company, engages in the research and development of all-natural drugs in the United States.

AMDL, Inc., (AMEX: ADL) headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products.

Amgen (AMGN) is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology

Amylin Pharmaceuticals Inc. (NasdaqGS: AMLN) a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines for the treatment of diabetes, obesity, and cardiovascular diseases in the United States..

Anadys Pharmaceuticals Inc. (NasdaqGM:ANDS) engages in the discovery, development, and commercialization of small-molecule medicines for the treatment of hepatitis, other serious infections, and cancer.

Anesiva, Inc. (NasdaqGM: ANSV) engages in the discovery, development, and commercialization of therapeutic treatments for pain management and inflammation. It has four products in various stages of development.

Anika Therapeutics Inc. (NasdaqGS: ANIK) engages in the development, manufacture, and commercialization of therapeutic products for tissue protection and healing. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body.

AnorMED Inc. (NasdaqGM: ANOR) is a biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology.

Antigenics Inc. (NasdaqGM: AGEN) engages in the development of technologies and products to treat cancers, infectious diseases, and autoimmune disorders, primarily based on immunological approaches.

Applied DNA Sciences, Inc. (OTCBB: APDN), a development stage company, provides DNA-embedded biotechnology security products that protect corporate and intellectual property from counterfeiting, fraud, piracy, product diversion, and unauthorized intrusion. The company offers DNA security systems, supply-chain management systems, and anti-counterfeit solutions. It offers various DNA products, including markers, anti-counterfeit inks, labels, and chips. The company markets and sells its products primarily to corporations and government agencies principally in the United States and Europe. Applied DNA Sciences was incorporated in 2002 and is headquartered in Los Angeles, California.

Ariad Pharmaceuticals Inc. (NasdaqGM: ARIA) is developing breakthrough medicines that regulate cell-signaling pathways implicated in cancer. Their pipeline includes a series of small molecule product candidates that provide targeted and highly potent anti-cancer activity to treat solid tumors and hematologic cancers, as well as the spread of tumors to distant sites.

ASI Technology Corp. (OTCBB: ASIT.OB) a development stage company, engages in development and commercialization of the plasma technologies. It owns plasma sterilization and decontamination technology, which employs resistive electrodes to produce atmospheric pressure plasma that is primarily used in military, medical, and food and package sterilization.

Aspreva Pharmaceuticals Corporation (NasdaqGS: ASPV) engages in the identification, development, and commercialization of new indications for approved drugs and late stage drug candidates for patients living with less common diseases. It is conducting clinical development programs to evaluate CellCept in the treatment of autoimmune diseases, such as lupus nephritis, myasthenia gravis, and pemphigus vulgaris; as well as in the treatment of cardiovascular disease.

Auriga Laboratories, Inc., (OTCBB:ARGA) a specialty pharmaceutical company, engages in the development of pharmaceutical products for respiratory, dermatology, and psychiatry markets.

AVAX Technologies Inc. (OTCBB: AVXT.OB) engages in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. The company primarily focuses on the development of an autologous cell vaccine, referred to as M-Vax, which is designed as an immunotherapy for the postsurgical treatment of late stage melanoma. It also focuses on the development of autologous cell vaccine technology for the treatment of ovarian cancer, lung cancer, and other cancers.

Avicena Group Inc (OTCBB: AVGO.OB) develops pharmaceutical and therapeutic products. It primarily focuses on the development of orphan drug indications to treat patients with rare diseases.

Beijing Med-Pharm Corporation (NASDAQ: BJGP) through its subsidiaries, is a pharmaceutical marketing and distribution company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China and is pursuing partnerships with other companies seeking to enter the Chinese pharmaceutical market. It is the only U.S. public company to offer industry partners a comprehensive suite of market-entry services in China that includes pre-market entry analysis, clinical trial management, product registration, market research, as well as pharmaceutical marketing and distribution. The company provides distribution services for a wide range of products, including Western medicines, traditional Chinese medicines, bio-chemical medicines, medical applications, branded generic pharmaceuticals, over-the-counter healthcare products, and home healthcare supplies and equipments. Beijing Med-Pharm's proprietary portfolio primarily focuses on women's health and pediatrics.

Bio-Bridge Science, Inc. (OTCBB: BGES) and its subsidiaries are engaged in the business of developing and commercializing biological products particularly for HIV treatment and prevention. They develop HIV vaccines for both preventive and therapeutic purposes. They intend to conduct clinical trials for such potential products in China, taking advantage of the low cost of conducting such tests in China and China’s “Green Mile” drug approval process for anti-AIDS drugs. They are in the process of building a laboratory facility in Beijing, China, which we intend to make in compliance with Good Manufacturing Practice regulation. The facility is intended to be used to conduct the clinical trials of HIV vaccine product.

BIO-key (OTC: BKYI) develops and delivers advanced identification solutions and information services to law enforcement departments, public safety agencies, government and private sector customers.

Bio-Matrix Scientific Group, Inc. (OTC.PK: BMXG) is a development stage company in the business of medical devices and monitoring systems research, development and commercialization. Bio-Matrix Scientific Group Inc. is aligning itself with partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems.

Barrier Therapeutics Inc. (NasdaqGM: BTRX) is a pharmaceutical company focused on developing and commercializing products in the field of dermatology. They are committed to developing innovative products that address major medical needs in the treatment of dermatological diseases and disorders of the skin.

BioCryst Pharmaceuticals Inc. (NasdaqGM: BCRX) engages in the design, optimization, and development of novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to use structure-based drug design to discover and develop small molecule pharmaceuticals.

BioDelivery Sciences International Inc. (NasdaqCM: BDSI) a specialty pharmaceutical company that is exploiting its licensed and proprietary patented drug delivery technologies to develop and commercialize, either on our own or in partnerships with third parties, clinically-significant new formulations of proven therapeutics.

Bioenvision Inc. (NasdaqGM: BIVN) engages in the acquisition, development, distribution, and marketing of compounds and technologies for the treatment of cancer, autoimmune disease, and infection.

Biogen, Inc. (BGEN)is the world's oldest independent biotechnology company and a leader in biologics research, development and manufacturing. A pioneer in leading edge research in immunology, neurobiology and oncology, Biogen brings novel therapies to improve patients' lives around the world through its global marketing capabilities.

BioMarin Pharmaceutical Inc. (NasdaqGM: BMRN) engages in the development and commercialization of biopharmaceuticals for serious diseases and medical conditions. Its product portfolio comprises two approved products and various investigational product candidates. Approved products include Aldurazyme and Naglazyme.

Biomira Inc. (NasdaqGM: BIOM) is a biotechnology company applying its leading technology in immunotherapy and organic chemistry for the development of cancer therapeutics. The Company's commitment to the development of products for the treatment of cancer is currently focused on synthetic therapeutic vaccines and innovative strategies for immunotherapeutic treatment of cancer.

Bionovo Inc. (NASDAQ: BNVI) is focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo’s lead drug candidate, MF101, recently showed positive results in a double-blind, placebo-controlled randomized Phase 2 trial for the treatment of hot flashes associated with menopause. Bionovo’s lead anti-cancer agent, BZL101, is currently undergoing multi-center Phase 1/2 clinical testing for late stage breast cancer. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit www.bionovo.com.

Biopure Corp. (NasdaqGM: BPUR) engages in the development, manufacture, and marketing of pharmaceuticals, called oxygen therapeutics. Its pharmaceuticals are administered intravenously to increase oxygen transport to the body’s tissues.

Biosante Pharmaceuticals Inc. (AMEX: BPA) a development stage biopharmaceutical company, engages in the development of a pipeline of hormone therapy products. BioSante's hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. Symptoms treated with hormone therapy in men include impotence, diminished sex drive, muscle weakness and osteoporosis. Symptoms in menopausal women include hot flashes, vaginal atrophy, decreased libido and osteoporosis.

BioSphere Medical, Inc. , (NASDAQ:BSMD) a medical device company based in Rockland, Massachusetts, seeks to pioneer and commercialize minimally invasive diagnostic and therapeutic applications based on proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments

BioTime Inc. (OTCBB: BTIM.OB) engages in the development of synthetic plasma expanders, blood volume substitute solutions, and organ preservation solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine.

Biovest International Inc. (OTCBB: BVTI.OB) on the production and contract manufacturing of biological drugs and products from small through commercial scale in the United States. It manufactures instruments and disposables used in the hollow fiber production of cell culture products.

Boston Life Sciences Inc. (NasdaqCM: BLSI) engages in the research and clinical development of biopharmaceutical products for the diagnosis and treatment of central nervous system (CNS) diseases, Parkinson’s disease (PD), and cancer in the United States.

Brainstorm Cell Therapeutics Inc. (OTCBB: BCLI.OB) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to treat diseases such as Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) and Multiple Sclerosis (MS).

Bristol-Myers Squibb Company (NYSE: BMY)

Cadus Corp. (OTCBB: KDUS.OB) engages in the ownership and licensing of yeast-based drug discovery technologies. Its core yeast technology is used for developing drug discovery assays.

Cambrex Corp. (NYSE: CBM) provides products and services to accelerate drug discovery, development, and manufacturing processes for human therapeutics worldwide. It operates in three segments: Bioproducts, Biopharma, and Human Health. The Bioproducts segment offers research products. The Biopharma segment provides contract biopharmaceutical process development and manufacturing services. The Human Health segment produces active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products; and other fine custom chemicals derived from organic chemistry.

CardioVascular BioTherapeutics Inc. (OTCBB: CVBT.OB) a development stage company, focuses on the development and marketing of a protein drug for the treatment of coronary artery disease. The company drug candidate Cardio Vascu-Grow facilitates the growth of new blood vessels in the heart and surrounding vascular system.

Cardium Therapeutics Inc. (OTCBB: CDTP.OB) a development stage medical technology company, engages in the development, manufacture, and sale of therapeutic products for cardiovascular and related indications, which are healthcare priorities for adults in the United States, Europe, and others. It focuses on the clinical development and commercialization of DNA-based, myocardial-derived, growth factor therapeutics for the treatment of coronary artery disease and heart attacks.

CEL-SCI Corp. (AMEX: CVM) is involved in the research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The Company’s core capabilities include drug discovery, research, development and manufacturing of complex biological substances.

Celgene Corporation (NasdaqGS: CELG) engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immunological diseases through regulation of genomic and proteomic targets.

Cell Genesys, Inc. (NasdaqGM: CEGE) engages in the research, development, and commercialization of biological therapies for patients with cancer. It develops cell-based immunotherapies and oncolytic virus therapies to treat various types of cancer. The company’s clinical stage cancer programs comprise cell- or viral-based products that have been genetically modified during product development to impart disease-fighting characteristics.

Cell Therapeutics Inc. (NasdaqGM: CTIC) engages in the development, acquisition, and commercialization of treatments for cancer. The company is developing XYOTAX, a chemotherapeutic agent, which links paclitaxel to a polyglutamate polymer, for the treatment of non-small cell lung cancer, ovarian, and other cancers; Pixantrone, an anthracycline derivative, for the treatment of non-Hodgkin’s lymphoma (NHL) and relapsed NHL; and CT-2106, which is in phase I/II studies for colorectal and ovarian cancers.

Celsion Corporation , (AMEX: CLN ) a biotechnology company, engages in the development and commercialization of treatment systems for the treatment of cancer and other diseases in the United States. It develops and commercializes oncology drugs, including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems

Ceragenix Phamaceuticals Inc. (OTCBB: CGXP.OB) is an emerging biopharmaceutical company developing next generation prescription therapies based on its platform of proprietary surface active technologies — skin Barrier Repair Technology (BRT) and a new class of broad spectrum anti-infectives called Ceragenins™.

Cerus Corp. (NasdaqGM: CERS) engages in the research, development, clinical testing, and commercialization of blood safety systems, immunotherapies for cancer and infectious disease. It develops cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens.

Charles River Laboratories International Inc. (NYSE: CRL) engages in the production and sale of research models that advance the drug discovery and development process. It offers animal research models, principally purpose-bred rats, mice, and other rodents required in research and development for new drugs, devices, and therapies.

Chelsea Therapeutics International Ltd. (NasdaqCM CHTP) engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of immunological diseases.

CHINA BIOPHARMA INC (OTCBB: CBPC.OB) develops, produces, and distributes human vaccine products in China. Its products primarily consist of human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis.

China Kangtai Cactus Biotech, Inc. (OTCBB: CKGT ) is a market-leading cactus grower and producer of cactus-related products with over 387 acres of plants and an active R&D group that holds 15 product patents and is seeking another 16 in a variety of product categories. China Kangtai's high-quality products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 14 provinces and 4 municipalities.

Chiron Corp (CHIR) is a global pharmaceutical company that leverages a diverse business model to develop and commercialize high-value products.

Circle Group Holdings (OTCBB: CRGQ ) Pioneer of emerging technology companies. The Company provides small business infrastructure, funding and substantial intellectual capital to bring important and timely life-changing technologies to market through all early phases of the commercialization process. Its FiberGel Technologies subsidiary owns the worldwide rights to Z-Trim for all fields of use. Invented over many years by Outstanding Senior Research Scientist Dr. George Inglett at the United States Department of Agriculture (USDA), Z-Trim is a patented, zero calorie, multi-functional, fiber food ingredient from corn that lowers calories and fat in most foods without affecting taste or texture.  http://ztrim.com

Clearant, Inc. (OTCBB: CLRI.OB) engages in the development and marketing of pathogen inactivation technology. The company acquires, develops, and markets its pathogen inactivation technology, the Clearant Process to producers of biological products, such as devitalized musculoskeletal tissue allograft implants, plasma protein therapeutics, recombinant protein therapeutics, medical devices, and blood and blood-related products.

Cleveland BioLabs, Inc. (NasdaqCM:CBLI) is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.

Clinical Data, Inc. (NasdaqNM: CLDA) is a worldwide leader in providing comprehensive molecular and pharmacogenomics services as well as clinical diagnostics to improve patient care. Clinical Data's Therapeutic Diagnostics(TM) division, PGxHealth, builds upon existing assets acquired from Genaissance Pharmaceuticals in the areas of genomics-based, clinical diagnostics, therapeutic efficacy and safety biomarker development for drug utilization. PGxHealth plans to develop and introduce novel Therapeutic Diagnostics in combination with new and existing therapeutics. Clinical Data's Pharmacogenomics and Molecular Services(TM) division, Cogenics, consolidates the operations of Genaissance Pharmaceuticals, Inc., Lark Technologies, Inc. and Icoria, Inc., each acquired during 2005. Cogenics provides a comprehensive range of molecular and pharmacogenomics services to pharmaceutical, biotech, academia, agricultural, and government clients. These services are offered in both research and regulated environments and have applications across the lifecycle of pharmaceutical product development, including pharmacovigilance requirements post launch. Clinical Data's Vital Diagnostics division consolidates the operations of Clinical Data Sales & Service, Inc., Vital Scientific NV, Vital Diagnostics Pty. Ltd., and Electa Lab s.r.l. This division serves the clinical laboratory in the traditional in-vitro diagnostics market worldwide with a focus on the physician's office, hospital and small-to-medium sized laboratory segments. With customers in approximately 100 countries, Vital Diagnostics has achieved a leading market share for instruments and reagents sold into moderately complex physicians' office laboratories within the United States.

Cobalis Corp. (OTCBB: CLSC.OB) a development stage company, engages in the development and commercialization of medications for allergic diseases.

CombinatoRx Inc. (NasdaqGM: CRXX) focuses on the development of medicines built from synergistic combinations of approved drugs. Its portfolio consists of seven product candidates targeting multiple immuno-inflammatory diseases and cancer. The company's clinical and preclinical pipeline includes treatments in development for cancer and rheumatoid arthritis.

Compugen Ltd. (NasdaqGM: CGEN) operates as a genomics-based drug and diagnostic discovery company. It engages in the discovery, validation, and commercialization of therapeutic and diagnostic biomarker product candidates. It has three research and development units: Therapeutics unit, Diagnostic Biomarkers unit, and Research and Discovery unit. The Therapeutics unit selects and validates therapeutic protein product candidates that it discovers in-house with the use of its predictive discovery engines. The Diagnostic Biomarkers unit selects and prioritizes diagnostic product candidates that it discovers in-house with the use of its predictive discovery engines. The Research and Discovery unit discovers therapeutic protein and diagnostic product candidates through its LEADS computational biology platform and discovery engines.

Corautus Genetics Inc. (NasdaqCM: VEGF) engages in the development and commercialization of gene therapy products for the treatment of cardiovascular and peripheral vascular disease.

Corcept Therapeutics Inc. (NasdaqGM: CORT) develops drugs for the treatment of severe psychiatric and neurological diseases.

CoTherix Inc. (NasdaqGM: CTRX) a development stage company, engages in biopharmaceutical operations. It focuses on licensing, developing, and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. The company offers Ventavis inhalation solution for the treatment of pulmonary arterial hypertension in patients with NYHA Class III or IV symptoms.

Critical Therapeutics Inc. (NasdaqGM: CRTX) engages in the discovery, development, and commercialization of products to treat respiratory, inflammatory, and critical care diseases through the regulation of the body’s inflammatory response.

CryoPort, Inc (OTC.PK: CYRX) develops leading edge, proprietary, technology driven shipping and storage products for use in the rapidly growing global biotechnology and pharmaceutical sectors. The products developed by CRYOPORT are essential components of the infrastructure required for the testing and research components that make up the foundation of the pharmaceutical and biotechnology industries. CRYOPORT has used the innovative technologies developed for aerospace and other industries to develop products that offer a more cost effective and reliable solution to the currently used dry ice equipment.

CuraGen Corp. (NasdaqGM: CRGN) It develops novel protein, antibody, and small molecule therapeutics in the areas of oncology, inflammatory diseases, and diabetes. The company also commercializes advanced technologies for genetic analysis to perform comprehensive determination of the nucleotide sequence of genomes and ultra-deep sequencing of accurate detection of mutations in target genes of interest

Curis Inc. (NasdaqGM: CRIS) focuses on the discovery, development, and commercialization of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. Its product development approach involves using small molecules, proteins, or antibodies to modulate these regulatory signaling pathways. Curis uses its product development approach to produce various preclinical product candidates in the fields of cancer, neurological disorders, kidney diseases, cardiovascular diseases, and hair growth regulation.

CV Therapeutics Inc. (NasdaqGM: CVTX) engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cardiovascular diseases.

Cypress Bioscience Inc. (NasdaqGM: CYPB) provides products for the treatment of functional somatic syndromes and other central nervous system disorders in the United States.

CytoDyn Inc. (OTCBB: CYDY.OB) engages in the research and development of a treatment for human immunodeficiency virus. The company uses monoclonal antibodies to protect the immune system of the body.

Cytokinetics Inc. (NasdaqGM: CYTK) is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. A number of commonly used drugs and a growing body of research validate the role that the cytoskeleton plays in a wide array of human diseases. Our focus on the cytoskeleton enables us to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease and other diseases.

Cytori Therapeutics, Inc. (NasdaqGM: CYTX) engages in the discovery and development of cell-based regenerative medicine therapies worldwide. It develops Celution system to automate its proprietary process and methods for separating, isolating, and concentrating stem and regenerative cells from adipose.

CytRx Corp. (NasdaqCM: CYTR) is a biopharmaceutical company engaged in the development of high-value therapeutics utilizing its core technologies in small molecule drugs, RNAi drug discovery and DNA vaccines.

Dendreon Corp. (NasdaqGM: DNDN) engages in the discovery, development, and commercialization of therapeutics that harness the immune system to fight cancer. Its product portfolio includes active immunotherapy, monoclonal antibody, and small molecule product candidates to treat a range of cancers.

Discovery Laboratories Inc. (NasdaqGM: DSCO) developing our proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory diseases. Surfactants are substances that are produced naturally in the lungs and are essential to the lungs' ability to absorb oxygen and to maintain proper airflow through the respiratory system. The absence or depletion of surfactants is involved in a number of respiratory diseases.

Diversa Corporation (NASDAQ: DVSA) engages in the discovery and development of protein-based products, such as enzymes and antibodies by applying its proprietary genomic technologies. The company focuses its integrated portfolio of technologies on the discovery, evolution, and production of molecules with agricultural, industrial, and chemical applications, such as enzymes, as well as optimized antibodies with pharmaceutical applications. Its primary areas of focus for internal product development comprise alternative fuels, specialty industrial processes, and health and nutrition.

DOR BioPharma Inc. (OTCBB: DORB.OB) is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents.

Dyadic International, Inc. (AMEX: DIL) is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes. Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products.

Dyax Corp (NasdaqNM: DYAX) a biopharmaceutical company principally focused on the discovery, development and commercialization of antibody-, protein- and peptide-based therapeutic products. The Company uses its proprietary and patented technology, known as phage display, to identify compounds with the potential for the treatment of various diseases. Dyax is utilizing phage display technology to build a portfolio of product candidates that it plans to develop and commercialize either on its own or with others. On behalf of collaborators, Dyax also uses phage display technology to identify compounds that can be used in therapeutics, diagnostic imaging, the development of research reagents and in purifying and manufacturing biopharmaceuticals. Using phage display, the Company has developed DX-88, which was shown in-vitro to be a high-affinity, high-specificity inhibitor of human plasma kallikrein. Dyax has also developed DX-890, a novel human neutrophil elastase inhibitor.

eGene, Inc. (OTCBB: EGEI.OB) engages in the development and manufacture of microfluidic, miniaturized digital analyzer systems, software, and consumables for biological materials testing applications.

Embrex Inc. (NasdaqGM: EMBX) engages in the development, sale, and lease of biological and mechanical products for the poultry industry in the United States and internationally. It offers the Inovoject system, a proprietary, automated in-the-egg injection system, which can process 20,000 to 70,000 eggs per hour and eliminates the need for manual, post-hatch injection of certain vaccines.

Encysive Pharmaceuticals Inc. (NasdaqGM: ENCY) engages in the discovery, development, and commercialization of novel, synthetic, and small molecule compounds. Its research and development programs are focused on the treatment and prevention of interrelated diseases of the vascular endothelium, the intravascular inflammatory process, and the vascular diseases.

EntreMed Inc. (NasdaqGM: ENMD) a clinical-stage pharmaceutical company focused on developing next generation multi-mechanism oncology and antiinflammatory drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes.

Enzon Pharmaceuticals Inc. (NasdaqGM: ENZN) engages in the development, manufacture, and commercialization of pharmaceutical products for the treatment of cancer and other life-threatening diseases in the United States and Canada.

Eugene Science, Inc. (OTC BB:EUSI) Based in Bucheon, Kyunggi-Do, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart disease product, CZ(TM), is a patented, nanoscience-based, water-soluble functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ(TM) is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol lowering efficacy.

EXACT Sciences Corp. (NasdaqGM: EXAS) an applied genomics company, develops proprietary DNA-based technologies for use in the detection of cancer. The company licenses its technologies for use in a commercial testing service and marketed under the name PreGen-Plus. PreGen-Plus is a noninvasive stool-based DNA testing service for the detection of colorectal cancer in the average-risk population.

Favrille Inc. (NasdaqGM:FVRL) focused on the research, development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. They have developed a proprietary technology that enables us to develop and manufacture active immunotherapy products that are designed to stimulate a patient's immune system to mount a specific and sustained response to disease.

FaceKey Corp. (OTC.PK: FEKY) headquartered in San Antonio, TX, is a biometrics technology provider whose mission is to provide supreme security measures for their customers by utilizing patented and proprietary biometric technologies that identify and allow access to authorized personnel. FaceKey's technology combines face and fingerprint recognition providing the highest level of security available, reducing fraud and providing better accountability.

FacePrint Global Solutions Inc. (OTCBB: FCPG) a developer and marketer of advanced technology identity solutions and related products

Fermavir Pharmaceuticals, Inc. (OTC BB: FMVR.OB) a development stage biotechnology company, holds licensed patents for a series of compounds for the treatment of viral diseases. It has patents for compounds for the treatment of varicella zoster virus (VZV), the causative agent for shingles and chickenpox, as well as human cytomegalovirus, which includes the viruses that cause chicken pox, mononucleosis, herpes labialis, and genitalis.

Forbes Medi Tech, Inc. (NasdaqNM: FMTI) a biopharmaceutical company dedicated to the research, development and commercialization of innovative prescription pharmaceutical and nutraceutical products for the prevention and treatment of cardiovascular and related diseases. Forbes' scientific platform is based on core sterol technology. By extracting plant sterols from by-products of the forestry industry, Forbes has developed cholesterol-lowering agents for use in pharmaceutical compounds, functional foods and dietary supplements.

Galton Biometrics (OTCPK: GALB)

Genaera Corp. (NasdaqCM: GENR) is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Genaera Corp’s research and development efforts are focused on anti-angiogenesis and respiratory diseases.

Genesis Bioventures, Inc., (GBIW.OTCBB) through its subsidiary, Biomedical Diagnostics, LLC, engages in identifying and funding biotechnology companies involved in the research and related product development in the fields of cancer and neurodegenerative diagnostics

Genentech, Inc. (DNA) is a biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs.

Gen-Probe (NASDAQ:GPRO) -Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people.

GeneThera Inc. (OTC BB: GTHA.OB) a development stage company, develops molecular assays for the detection of food contaminating pathogens, veterinary diseases, and genetically modified organisms primarily in the United States.

Genetronics, Inc. (GEB) Unique cancer therapy can selectively kill cancerous cells while preserving healthy tissue
Genetronics, Inc. is a leader in electroporation therapy with over 200 patents issued, allowed, or pending. Genetronics, Inc. utilizes its proprietary electroporation technology for the targeted intracellular delivery of therapeutic materials, concentrating on drugs, DNA vaccines, and gene therapies. In oncology, it has initiated Phase III clinical trials for the treatment of recurrent head & neck cancer, and has marketing approval in Europe. First sales are planned for 2005. In gene therapy, it has several collaborations with major biotechnology and pharmaceutical companies, such as Chiron, for the delivery of therapeutic genes or vaccines using electroporation.

Genitope Corp. (NasdaqGM: GTOP) focused on the research and development of novel immunotherapies for the treatment of cancer. Immunotherapy products are designed to utilize the immune system to combat diseases such as cancer.

Genta Inc. (NasdaqGM: GNTA) engages in the identification, development, and commercialization of drugs for the treatment of cancer and related diseases in the United States.

GenVec, Inc. (Nasdaq:GNVC) is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM) is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza.

GeoPharma Inc. (NASDAQ: GORX) engages in the manufacture, package, and distribution of various health-related products for companies worldwide. The company develops and manufactures a range of nutritional supplements; dietary supplements, and health and beauty care products for distribution through various outlets; over-the-counter drugs and repackages generic drugs; and foods for the low-carbohydrate lifestyle.

Genzyme Gen (GENZ) is a global biotechnology that develops and markets therapeutic products and services for serious diseases. The Company's broad product portfolio is focused on rare genetic disorders, renal disease and osteoarthritis and more.

Geron Corporation (GERN) is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for applications in oncology and regenerative medicine, as well as research tools for drug discovery. The Company's product development programs are based on three patented core technologies: telomerase, human embryonic stem cells and nuclear transfer. Telomerase is an enzyme that, when introduced into normal cells, is capable of restoring telomere length, consequently increasing the lifespan of cells without altering their normal function or causing them to become cancerous; human embryonic stem cells enable the development of transplantation therapies by providing standard starting material for the manufacture of cells and tissues, and nuclear transfer is used for the creation of cloned animals. (YAHOO)

Gilead Sci (GILD) is a biopharmaceutical company that discovers develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases worldwide.

GTC Biotherapeutics Inc. (NasdaqGM: GTCB) engages in the development, production, and commercialization of therapeutic proteins through transgenic animal technology in the United States. It focuses on developing and producing therapeutic products for use in critical care, including recombinant forms of therapeutic proteins that are extracted from human blood plasma.

GTX Inc. (NasdaqGM: GTXI) engages in the discovery, development, and commercialization of therapeutics for cancer and serious conditions related to men’s health. Its drug discovery and development programs are focused on small molecules that modulate the effects of estrogens and androgens, two essential classes of hormones.

Halozyme Therapeutics Inc. (AMEX: HTI) engages in the development and commercialization of recombinant human enzymes for the infertility, palliative care, drug delivery, and oncology treatments

Hana Biosciences Inc. (NasdaqGM: HNAB) a development stage biopharmaceutical company, engages in the acquisition, development, and commercialization of products for cancer care. Its product candidates in early-stage development include Zensana, an ondansetron oral spray, to alleviate chemotherapy-induced nausea and vomiting; Talotrexin (PT-523), for the treatment of various solid tumors and hematological malignancies, including nonsmall cell lung cancer, acute lymphocytic leukemia, and cervical cancers; and Ropidoxuridine (IPdR), for the treatment of colorectal, gastric, pancreatic, and liver cancers.

Health Discovery Corp. (OTCBB: HDVY.OB) operates as a biotechnology-oriented biomarker and pathway discovery company in the United States. It discovers a subset of genes that separates BPH from prostate cancer and BPH from normal; an AIDS gene set, which separates AIDS brain cells from nonAIDS brain cells; a subset of genes that indicates disease progression from less malignant to additional malignant forms of prostate cancer; and a set of leukemia genes, which separates ALL-T-cell leukemia from ALL-B-cell leukemia.

Health Sciences Group Inc. (OTCBB: HESG.OB) provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system.

Hemispherx Biopharma, Inc. (AMEX: HEB) engages in the clinical development and manufacture of drugs for the treatment of viral and immune-based chronic disorders.

Hemobiotech Inc. (OTCBB: HMBT.OB) engages in the research and development of human blood substitute technology licensed from Texas Tech University Health Science Center School of Medicine (Texas Tech) in Texas. It focuses primarily on the production of HemoTech, an oxygen-carrying solution that performs as red blood cells for use in Phase I U.S. clinical trials.

Heska Corp. (NasdaqCM: HSKA) engages in the discovery, development, manufacture, marketing, sale, distribution, and support of veterinary products in the United States. The company operates in two segments, Core Companion Animal Health (CCA); and Other Vaccines, Pharmaceuticals, and Products (OVP). The CCA segment offers diagnostic and monitoring instruments and supplies; single use diagnostic and point-of-care tests; vaccines; and pharmaceuticals, primarily for canine and feline use. The OVP segment provides private label vaccine and pharmaceuticals, primarily for cattle, as well as for other animals, including small mammals, horses, and fish.

Hollis-Eden Pharmaceuticals Inc. (NasdaqGM: HEPH) a development stage pharmaceutical company, engages in the discovery, development, and commercialization of products for the treatment of diseases and disorders, in which the body is unable to mount an immune response.

Idenix Pharmaceuticals Inc. (NasdaqGM: IDIX) engages in the discovery, development, and commercialization of drugs for the treatment of human viral and other infectious diseases. It focuses on the treatment of infections caused by the hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).

Idec Pharm (IDPH) is a biopharmaceutical company engaged primarily in the research, development, manufacture and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases.

Idera Pharmaceuticals Inc. (AMEX: IDP) is a biotechnology company engaged in the discovery and development of novel therapeutics that modulate immune responses through Toll-like receptors (TLR) for the treatment of multiple diseases.

IDM Pharma, Inc. (NasdaqGM:IDMI) is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. IDM is currently developing two types of products designed to destroy cancer cells by activating innate immunity, and prevent tumor recurrence by triggering a specific adaptive immune response.

IGI Inc. (AMEX: IG) engages in the production and marketing of cosmetics and skin care products primarily in the United Stares. The company, through its licensed Novasome lipid vesicle encapsulation technologies, engages in the manufacture of various dermatological, consumer, skin care, and hair care products for third parties.

Illumina Inc. (NasdaqGM: ILMN) engages in the development and marketing of tools for the analysis of genetic variation and function primarily in the United States and internationally. Its single nucleotide polymorphism (SNP) genotyping product comprises Sentrix Array Matrix, which uses a universal format that allows it to analyze various sets of SNPs.

Imclone Systems Inc. (NasdaqGS: IMCL) develops a portfolio of biologic treatments for the medical needs of patients with cancer. The company offers ERBITUX, an antibody, for use in combination with irinotecan in the treatment of patients with EGFR-expressing, metastatic colorectal cancer, who are refractory to irinotecan-based chemotherapy; and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer, who are intolerant to irinotecan-based chemotherapy.

Immtech Pharmaceuticals, Inc. (AMEX: IMM) engages in the development and commercialization of oral drugs to treat infectious diseases. It also extends its proprietary aromatic cation technology platform to the treatment of cancer, diabetes, and other diseases.

Immune Response Corp. (OTCBB: IMNR.OB) focuses on the development of various products to treat autoimmune and infectious diseases. It offers NeuroVax, which is based on T-cell receptor peptide technology for the treatment of multiple sclerosis; and IR103 and Remune for the treatment of Human Immunodeficiency Virus (HIV).

Immunogen Inc. (NasdaqGM:IMGN) researches and develops antibody-based anticancer therapeutics in the United States. It develops novel and targeted therapeutics for the treatment of cancer using its Tumor-Activated Prodrug (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent.

Immunomedics Inc. (NasdaqGM: IMMU) develops monoclonal antibody-based products for the treatment of cancer, autoimmune, and other serious diseases. Its lead product candidate is epratuzumab, which is in two pivotal Phase III trials for the treatment of patients with moderate and severe lupus.

Incyte Corporation (NasdaqGM: INCY) is a drug discovery and development company, which focuses on building a proprietary product pipeline of small molecule orally-available drugs to treat cancer, inflammation, human immunodeficiency virus (HIV), and diabetes.

Indevus Pharmaceuticals Inc. (NasdaqGM: IDEV) engages in the acquisition, development, and commercialization of products in the fields of urology, gynecology, and infectious diseases.

Inhibitex Inc. (NasdaqGM: INHX) a development stage company, engages in the discovery, development, and commercialization of novel antibody based products for bacterial and fungal hospital-associated infections.

Inncardio, Inc. (OTCBB: ICDO.OB) a development stage company, engages in the research and development of pharmaceutical products to treat cardiovascular disease and associated metabolic disorders.

Insmed Inc. (NasdaqGM: INSM) engages in the discovery and development of drug candidates for the treatment of metabolic diseases and endocrine disorders in the United States.

Integramed America Inc. (INMD) IntegraMed America, Inc. provides business services to a national network of 28 fertility centers in 90 locations across the United States; distributes pharmaceutical products and treatment financing programs directly to consumers; and operates the Web site http://www.integramed.com, a leading fertility portal. The IntegraMed network includes 158 physicians and Ph.D. scientists. Network membership is limited to one practice per metropolitan area, yet one of every five procedures in the U.S. is performed in an IntegraMed practice. IntegraMed provides more services to both consumers and medical providers in the fertility field than any other consortium

InterMune Inc. (NasdaqGM: ITMN) a biopharmaceutical company focused on developing and commercializing innovative therapies in pulmonology and hepatology.

International Stem Cell (OTCBB: ISCO) is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy.

IR BioSciences Holdings, Inc., (OTCBB: IRBO) through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera® and its derivatives Radilex(TM) and Viprovex®, which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system.

Invitrogen Corp. (NasdaqGS: IVGN) provides products and services that support academic and government research institutions, as well as pharmaceutical and biotechnology companies. The company operates in two segments, BioDiscovery and BioProduction. BioDiscovery segment offers functional genomics, cell biology, and drug discovery product lines. BioProduction segment offers Gibco cell culture products and BioReliance services. Gibco cell culture products consist of sera, cell, tissue culture media, and reagents that are used in life sciences research and in processes to grow cells in the laboratory, as well as to produce pharmaceuticals and other materials made through cultured cells.

Iomai Corporation (NasdaqGM: IOMI) focuses on the discovery, development, and commercialization of vaccines and immune system stimulants delivered to the skin. Its vaccines and immune system stimulants are delivered through a needle-free technology, known as transcutaneous immunization. The technology targets Langerhans cells, a specialized component of the immune system located in the outer layers of the skin for the delivery of adjuvants or antigens.

Kangtai Cactus Biotech, Inc. (OTCBB: CKGT),cactus grower and producer of cactus-related products with over 387 acres of plants and an active R&D group that holds 15 product patents and is seeking another 16 in a variety of product categories. China Kangtai's high-quality products are sold throughout China in supermarkets, food stores, hotels and restaurants through a growing distribution network that has currently covered 14 provinces and 4 municipalities.

Keryx Biopharmaceuticals (NasdaqNM: KERX ) a biopharmaceutical company focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinoid compound, for the treatment of diabetic nephropathy, for which Keryx recently commenced its U.S.-based Phase II/III clinical program. Additionally, Keryx is developing 3 clinical-stage oncology compounds including KRX-0401, a novel, oral, first- in-class AKT inhibitor in Phase II. Keryx also has an active in-licensing and acquisition program designed to identify and acquire clinical-stage drug candidates.

Kiwa Bio-Tech Products Group Corporation (OTCBB: KWBT ) The Company develops, manufactures, distributes and markets innovative, cost-effective, and environmentally safe bio-technological products for agricultural and natural resources and environmental conservation. The Company's products are designed to enhance the quality of human life by increasing the value, quality and productivity of crops and decreasing the negative environmental impact of chemicals and other wastes.

Kosan Biosciences Inc. (NasdaqGM: KOSN) is an established cancer therapeutics company with an industry-leading position in the development of Hsp90 inhibitors and epothilones with best-in-class potential. Kosan has four clinical compounds generating positive anti-cancer activity, an early-stage, advancing pipeline, validating corporate partnerships and a strong proprietary position.

La Jolla Pharmaceutical Co. (NasdaqGM: LJPC) engages in the research and development of specific therapeutic products for the treatment of various life-threatening antibody-mediated diseases in the United States. The company focuses on the discovery and development of proprietary therapeutics, called Toleragens, which target and suppress the production of specific disease-causing antibodies without affecting the protective functions of the immune system.

Lev Pharmaceuticals, Inc. (OTCBB: LEVP.OB) a development stage biopharmaceutical company, engages in the development and commercialization of therapeutic products for the treatment of inflammatory diseases. The company develops esterase inhibitor (C1-INH), a phase III clinical trials product, for the treatment of hereditary angioedema, which is a genetic disorder, characterized by episodic attacks of edema in the extremities, face, abdomen, and the airway passages.

LifeCell Corp. (NasdaqGS: LIFC) engages in the development and marketing of human-derived tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgical procedures to repair soft tissue defects. It produces a regenerative human tissue matrix, a three-dimensional structure that contains vascular channels, proteins, and growth factor binding sites, that provide a template for the regeneration of normal human tissue.

Lifecore Biomedical Inc. (NasdaqGM: LCBM) manufactures biomaterials and medical devices for use in various surgical markets, as well as and provides related specialized contract aseptic manufacturing services in the United States and internationally. It has two divisions, Hyaluronan and Oral Restorative. The Hyaluronan division develops and manufactures products utilizing hyaluronan, a naturally occurring polysaccharide that is distributed in the extracellar matrix of connective tissues in both animals and humans. The Hyaluronan division markets its products through original equipment manufacturers and contract manufacturing alliances in ophthalmologic and orthopedic surgery, and veterinary medicine.

LipidViro Tech Inc. (OTCBB: LPVT.OB) an early-stage biotechnology company, engages in research and development of d-OSAB Therapy, a treatment targeting cardiovascular disease and stroke; and PathPure, a purification process for production of pathogen-free biologics.

Lipid Sciences (NasdaqNM: LIPD ) a development-stage biotechnology company that is researching and developing products and processes intended to treat major medical conditions in which lipids, or fat components, play a key role. The Company's technologies are based on a process that selectively removes lipids from proteins. This delipidation process has the potential for far-reaching implications related to human health. It may provide an effective therapeutic effect on many infectious agents, including the viruses that cause AIDS, Hepatitis B and Hepatitis C, as well as reverse cardiovascular and cerebrovascular disease.

Liska Biometry (OTCBB: LSKA) develops fingerprint biometric solutions enabling fast individual authentication, precise identification searches, and cross-platform data interoperability.

Lorus Therapeutics Inc. (AMEX: LRP) engages in the discovery, research, and development of anticancer therapies. Its anticancer pipeline includes immunotherapy, small molecule compounds, and antisensetechnology.

Lpath Inc. (OTCBB: LPTN.OB) operates as a drug discovery company in the United States. It develops therapeutics for diseases, which involve changes in the activity and/or production of sphingolipids. The company’s drug development programs include Sphingomab, for the treatment of cancer, macular degeneration, chronic and acute inflammatory disease, and post-MI heart failure; Lpathomab, for the treatment of Cancer, as well as AMD and inflammatory disease; Lysomab, for cancer; Sphingomab ELISA-based assay, for Cancer and CVD diagnostic; and Lpathomab ELISA-based assay, for Cancer diagnostic.

Manhattan Pharmaceuticals Inc. (AMEX: MHA) engages in the development and commercializing of biomedical and pharmaceutical technologies in the United States. The company engages in researching and developing three biomedical technologies: Oleoyl-estrone, an orally administered therapeutic for weight loss; PTH (1-34), for the treatment of psoriasis and additional hyperproliferative skin disorders; and Lingual spray propofol, a lingual spray technology to deliver propofol for preprocedural sedation prior to diagnostic, therapeutic, or endoscopic procedures.

MannKind Corp. (NasdaqGM: MNKD) engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer primarily in the United States and Europe.

Martek Biosciences Corp. (NasdaqGS: MATK) engages in the development, manufacture, and sale of products derived from microalgae and other microbes primarily in the United States. Its products include nutritional oils used in infant formula, nutritional supplements, and food fortification ingredients, and fluorescent markers for diagnostics and rapid miniaturized screening.

Medarex Inc. (NasdaqGM: MEDX) engages in the discovery, development, and commercialization of human antibody-based therapeutics to treat principally cancer, inflammation, autoimmune disorders, and infectious diseases.

Medco Health Solutions, Inc. (NYSE:MHS) is a leader in managing prescription drug benefit programs that are designed to drive down the cost of pharmacy healthcare for private and public employers, health plans, labor unions and government agencies of all sizes. With its technologically advanced mail-order pharmacies and its award-winning Internet pharmacy, Medco has been recognized for setting new industry benchmarks for pharmacy dispensing quality. Medco serves the needs of patients with complex conditions requiring sophisticated treatment through its specialty pharmacy operation, which became the nation's largest with the 2005 acquisition of Accredo Health. Medco, the highest-ranked prescription drug benefit manager on Fortune magazine's list of "America's Most Admired Companies," is a Fortune 50 company with 2004 revenues of $35 billion.

Medicis Pharmaceutical Corp. (NYSE: MRX) focuses on the development and marketing of products for the treatment of dermatological, aesthetic, and podiatric conditions in the United States and Canada.

Medicure Inc. (AMEX: MCU) engages in the research, development, and commercialization of therapeutics for cardiovascular needs. It develops MC-1, which is in preclinical and clinical studies, for the treatment of acute cardiovascular events, such as acute coronary syndrome, coronary artery bypass, and graft surgery, as well as heart attacks to chronic conditions, including hypertension and metabolic syndrome.

Medimmune, Inc. (MEDI) is a global biotechnology company that uses advances in biological sciences to discover, develop, manufacture and market products that treat or prevent infectious diseases, immune system disorders and cancer.

Medivation, Inc. (AMEX: MDV) a development stage company, engages in the acquisition, development, and sale of biomedical technologies in the early-development stage of the research and development process. Its portfolio consists of three development programs, including Dimebon for the treatment of Alzheimer’s disease; Dimebon for the treatment of Huntington’s disease; and the MDV300 Series compounds for the treatment of hormone-refractory prostate cancer.

Memory Pharmaceuticals Corp. (NasdaqGM: MEMY) engages in the discovery and development of drug candidates for the treatment of central nervous system disorders in the United States. It offers drugs for neurological diseases associated with aging, such as Alzheimer’s disease, as well as certain psychiatric disorders, such as schizophrenia, bipolar disorder, and depression.

Merck & Co., Inc. (NYSE: MRK)

Meridian Bioscience, Inc. (NASDAQ:VIVO) a life science company, engages in the development, manufacture, sale, and distribution of diagnostic test kits primarily for respiratory, gastrointestinal, viral, and parasitic infectious diseases.

Metabasis Therapeutics Inc. (NasdaqGM: MBRX) engages in the discovery, development, and commercialization of drugs for chronic diseases involving pathways in the liver. The company provides products primarily for metabolic diseases, such as diabetes, hyperlipidemia, and liver diseases, including hepatitis and primary liver cancer.

MicroIslet Inc. (AMEX: MII) engages in the research, development, and commercialization of technologies in the field of transplantation therapy for patients with insulin-dependent diabetes. Its islet transplantation technology, licensed from Duke University, includes methods for isolating, culturing, cryopreservation, and immuno-protection of islet cells.

Micromet, Inc. (NasdaqGM: MITI) engages in the research, development, and commercialization of antibody-based products for cancer, and inflammatory and autoimmune diseases. Its drug development platform is based on its BiTE technology, an antibody-based format that uses the cytotoxic potential of T cells.

Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world’s challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide.

Momenta Pharmaceuticals Inc. (NasdaqGM: MNTA) engages in the sequencing and design of complex sugars for the development of improved versions of existing drugs. The company also engages in the development of novel drugs and the discovery of new biological processes.

Nabi Biopharmaceuticals (NasdaqGM: NABI) engages in the development and marketing of products for Gram-positive bacterial infections, hepatitis, kidney disease, and nicotine addiction. The company markets its Nabi-HB for the postexposure prevention of hepatitis B infection; Aloprim for the treatment of chemotherapy-induced hyperuricemia; and PhosLo for the treatment of hyperphosphatemia in end-stage renal failure patients primarily in the United States.

Nanogen Inc. (NasdaqGM: NGEN) provides human molecular diagnostic products to research, clinical laboratory, and point of care markets in North America, Europe, and Asia. The company’s diagnostic technologies focus on the identification of the nucleic acid sequences, gene variations, and gene expressions associated with genetic conditions and infectious diseases.

NanoViricides, Inc. (OTC.PK: NNVC), a biopharmaceutical company specializing in unique antiviral treatments that utilize its patented nanomicelle.

NanoLogix, Inc. (IFEC) NanoLogix, Inc., formerly known as InfectTech, Inc., is a technology application innovator of biogas products and services designed to assist in worldwide energy independence and reduce pollution from renewable, environmentally-friendly energy sources. NanoLogix is also engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons. Apoptosis is a method for inducing a genetically based induction of "cell suicide" in cells. The Company's 31 patents can be viewed by visiting http://www.infectech.com/intellectual_property.php.

Northfield Laboratories (NasdaqNM: NFLD ) Engaged in the development of a safe and effective alternative to transfused blood for use in the treatment of acute blood loss. Its PolyHeme blood substitute product is a solution of chemically modified hemoglobin derived from human blood. PolyHeme simultaneously restores lost blood volume and hemoglobin levels and is designed for rapid, massive infusion. PolyHeme requires no cross-matching and is therefore immediately available and compatible with all blood types. It has an extended shelf life compared to blood. The Company purchases indated and outdated blood from The American Red Cross and Blood Centers of America for use as the starting material for PolyHeme. It uses a proprietary process of separation, filtration and chemical modification to produce PolyHeme.

Nastech Pharmaceutical Co. Inc. (NasdaqGM: NSTK) engages in the development and commercialization of therapeutic products based on its molecular biology-based drug delivery technology for delivering both small and large molecule drugs, and small interfering RNA (siRNA) therapeutics.

NeoPharm Inc. (NasdaqGM: NEOL) is a publicly traded biopharmaceutical company dedicated to the research, discovery, and commercialization of new and innovative cancer drugs for therapeutic applications. NeoPharm has built its drug portfolio based on its two novel proprietary technology platforms: a tumor-targeting platform and the NeoLipid® drug delivery system.

Neose Technologies Inc. (NasdaqGM: NTEC) a clinical-stage biopharmaceutical company, develops proprietary drugs, focusing primarily on therapeutic proteins using its enzymatic technologies in the United States.

Neuro-Hitech, Inc. (OTCBB: NHPI.OB) a drug development company, engages in the development and commercialization of Huperzine A (HupA) and its analogues for Alzheimer’s disease and other degenerative neurological disorders.

Neurobiological Technologies Inc. (NasdaqCM: NTII) engages in the acquisition and development of central nervous system related drug candidates. It focuses on therapies for neurological conditions that occur in connection with dementia, alzheimer’s disease, ischemic stroke, neuropathic pain, and brain cancer.

Neurocrine Biosciences Inc. (NasdaqGS: NBIX) engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. It primarily develops drugs for the treatment of insomnia, anxiety, depression, various female and male health disorders, multiple sclerosis, diabetes, and other neurological and endocrine related diseases and disorders.

New River Pharmaceuticals Inc. (NasdaqGM: NRPH) focuses on developing novel pharmaceuticals for various markets for amphetamines and opioid analgesics.

New York Health Care Inc. (OTCBB: BBAL.OB) provides services of registered nurses and paraprofessionals to patients at their homes in the United States. Its services are supplied principally to contracts with healthcare institutions and governmental agencies.

Northwest Biotherapeutics Inc. (OTCBB: NWBT.OB) a development stage biotechnology company, engages in the discovery, development, and commercialization of immunotherapy products to treat cancer. It has two platform technologies, dendritic cell-based cancer vaccines and monoclonal antibodies for cancer therapeutics.

Novacea, Inc. (NasdaqGM: NOVC) is a biopharmaceutical company committed to creating a world-class drug development and commercialization organization that addresses the needs of cancer patients who have few treatment options.

Novartis AG (NYSE: NVS)

Novavax Inc. (NasdaqGM: NVAX) engages in the research, development, and commercialization of products for women’s health, infectious diseases, and cancer. Its primary product candidate, ESTRASORB, a topical emulsion for estrogen therapy is used for the treatment of vasomotor symptoms associated with menopause.

Novogen Ltd. (NasdaqGM: NVGN) engages in the discovery, development, manufacture, and marketing of products based on the isoflavoniod technology. Its product development program comprises a novel range of pharmaceuticals based on phenolic compounds in humans, and dietary supplements based on plant compounds known as isoflavones.

NPS Pharmaceuticals Inc. (NasdaqGM: NPSP) engages in the discovery, development, and commercialization of small molecules and recombinant proteins. The company’s product candidates are primarily used for the treatment of bone and mineral disorders, gastrointestinal disorders, and central nervous system disorders.

Nutrition 21 Inc. (NasdaqCM: NXXI) engages in the research, development, and commercialization of chromium-based nutrition products in the United States.

Nuvelo Inc. (NasdaqGM: NUVO) is a publicly traded biopharmaceutical company dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex, which recently completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical procedures.

Omrix Biopharmaceuticals, Inc. (NasdaqGM: OMRI) is a commercial-stage company that aims to develop and market innovative biosurgical and passive immunotherapy products, utilizing its proprietary protein purification technology and manufacturing know-how.

Onyx Pharmaceuticals Inc. (NasdaqGM: ONXX) develops therapies that target the molecular mechanisms implicated in cancer. Its primary product includes Nexavar, a novel, oral multiple kinase inhibitor of tumor cell proliferation and angiogenesis for the treatment of individuals with advanced kidney cancer, targeting RAF, VEGFR-2, PDGFR-â, KIT, FLT-3, and RET.

Opexa Therapeutics, Inc. (NasdaqGM: OPXA) engages in the development and commercialization of autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, cardiovascular diseases, and diabetes. These therapies are based on the company’s proprietary T-cell and stem cell technologies.

Oragenics Inc. (AMEX: ONI) primarily focuses on developing technologies associated with oral health, broad spectrum antibiotics, and other general health benefits. The company develops a replacement therapy, which is a painless topical treatment for protection from tooth decay; Mutacin 1140, an antibiotic with activity against gram-positive bacteria, including vancomycin-resistant staphylococcus aureus; and oral probiotic technology that employs naturally-occurring beneficial bacteria to promote oral and periodontal health.

Ortec International Inc. (OTCBB: OTCI.OB) a development stage tissue engineering company, engages in acquiring, developing, testing, and marketing of skin replacement product primarily in the United States. It develops proprietary and patented technology, which is used to stimulate the repair and regeneration of human skin.

Orthologic Corp. (NasdaqGM: OLGC) engages in healing musculoskeletal, orthopedic, dermal, and cardiovascular tissues through biopharmaceutical approaches.

Osiris Therapeutics, Inc. (NasdaqGM: OSIR) provides adult stem cell technology to physicians for the treatment and functional restoration of damaged or diseased tissues. It offers product indications in medical specialties, including oncology, cardiology, and orthopedics.

OSI Pharmaceuticals, Inc.(OSIP) Biotechnology Company focused on the discovery, development and commercialization of oncology products that both extend life and improve the quality-of-life for cancer patients worldwide.

OXiGENE, Inc. (OXGN) engages in the research and development of products for the treatment of cancer and certain eye diseases. The company focuses on the development of products for application as direct cancer treatment agents, particularly vascular targeting agents (VTAs).

Panacos Pharmaceuticals Inc. (NasdaqGM: PANC) engages in the discovery and development of small molecule oral drugs to treat human immunodeficiency virus (HIV) and other major human viral diseases.

PDL BioPharma Inc. (NasdaqGS: PDLI) engages in the discovery, development, and commercialization of therapies for life-threatening illness. The company markets three biopharmaceutical products: Cardene IV to reduce high blood pressure during or after surgery; Retavase for the improvement of ventricular function following acute myocardial infarction (AMI), the reduction of the incidence of congestive heart failure, and the reduction of mortality associated with AMI; and IV Busulfex, a chemotherapeutic agent that provides anti-tumor effect to eradicate residual malignancy, ablation of the bone marrow, and immunosuppression to prevent graft rejection.

Peregrine Pharmaceuticals Inc. (NasdaqCM: PPHM) engages in the research, development, and commercialization of novel therapeutics for cancer and viral diseases. It develops a portfolio of clinical and preclinical stage monoclonal antibody-based targeted therapeutics, including bavituximab that is in a multi center Phase I clinical trial for the treatment of solid cancers, as well as a multi center phase Ib clinical trial for the treatment of chronic HCV infection under its anti-phosphatidylserine immunotherapeutic technology platform.

Pfizer, Inc.(NYSE: PFE)

Pharmacia Corporation (NYSE: PHA)

Pharmacopeia Drug Discovery Inc. (NasdaqGM: PCOP) engages in the discovery and development of novel therapeutics primarily to address significant medical needs. Using proprietary technologies and processes, Pharmacopeia identifies, optimizes, and develops novel drug candidates through its internally-funded drug discovery programs and in collaborations with pharmaceutical and biotechnology companies.

Pharmos Corp. (NasdaqCM: PARS) engages in the discovery and development of novel therapeutics to treat various indications, including pain, inflammation, autoimmunity, and central nervous system disorders. Its proprietary technology platform focuses on the discovery and development of synthetic cannabinoid compounds.

Polydex Pharmaceuticals Ltd. (NasdaqCM: POLXF) engages in the research, development, manufacture, and marketing of biotechnology-based products for the human pharmaceutical market and bulk pharmaceutical intermediates for veterinary pharmaceutical industry worldwide.

Praecis Pharmaceuticals Inc. (NasdaqGM: PRCS) is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.

Pressure BioSciences, Inc. (NASDAQ: PBIO) is focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Progen Industries Ltd. (NasdaqCM: PGLA) is a globally focused biotechnology company committed to improving patient outcomes through discovery and development of small molecule-based cancer therapeutics.

Protalix BioTherapeutics, Inc. (AMEX: PLX) The Company is an emerging clinical stage biopharmaceutical company that is focused on developing and producing recombinant therapeutic proteins that are produced through a proprietary plant cell system.

Qiagen NV (NasdaqGS: QGEN) engages in the development, production, and distribution of biotechnology products and services for the separation, purification, and handling of nucleic acids (DNA/RNA) and proteins. It also manufactures and markets various other solutions for preanalytical sample processing and handling, as well as synthetic nucleic acids (RNAi), and related services and products.

QLT Inc. (NasdaqGS: QLTI) engages in the discovery, development, and commercialization of therapies primarily in the fields of ophthalmology and dermatology.

Questcor Pharmaceuticals, Inc. (AMEX: QSC) a specialty pharmaceutical company, engages in the manufacture and sale of pharmaceutical products for the treatment of diseases and disorders of the central nervous system.

Regeneron Ph